Artelo Biosciences' ART12.11 Shows Promising Antidepressant Effects in Preclinical Study

Artelo Biosciences Inc. (NASDAQ:ARTL) is one of the best-performing NASDAQ stocks according to analysts. On July 7, Artelo Biosciences announced positive preclinical efficacy data for its drug candidate, ART12.11, in a stress-induced depression model. These findings were presented at the 35th Annual International Cannabinoid Research Society/ICRS Symposium, which was held from July 6 to 10 this year, in Bloomington, Indiana.

The preclinical data was presented in a poster titled “ART12.11, A Novel Cannabidiol: Tetramethylpyrazine Cocrystal, Alleviates Stress-Induced Depressive Symptoms,” and showcased ART12.11’s unique dual-action profile. In male rats exposed to chronic stress, a 28-day treatment regimen with ART12.11 reversed behavioral impairments, showing antidepressant-like effects comparable to sertraline (Zoloft), which is a selective serotonin reuptake inhibitor/SSRI. ART12.11 also restored hedonic and social behaviors, such as sucrose preference and social motivation, to near-baseline levels, similar to sertraline.

ART12.11 has superior cognitive restoration. Unlike sertraline, ART12.11 reversed stress-induced deficits in both spatial and short-term memory without negatively impacting social memory, making it a differentiated therapeutic profile. This positions it as a potential next-generation treatment for depression and anxiety.

Artelo Biosciences Inc. (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company that develops and commercializes therapeutics that target lipid-signaling pathways in the US.

While we acknowledge the potential of ARTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.